KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome
Identifying a specific genetic change in bone marrow cells lets doctors spot which myelodysplastic syndrome patients are heading toward leukemia, so they can intervene earlier.
KMT2A-PTD is an independent predictor of leukemia transformation in MDS; 3-year cumulative incidence was ~50% with KMT2A-PTD versus ~19% without (IWG-PM cohort, P<.001); allogeneic HSCT significantly reduced both transformation risk and cumulative relapse incidence (17.6% vs 100%, P<.001). This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective_cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Multi-cohort validation (n=2,630) establishing KMT2A-PTD as an actionable independent predictor of leukemia transformation in MDS. Directly impacts transplant decision-making in a patient population at markedly elevated risk. Published in a specialized hematology journal with rigorous IWG-PM data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.